Previous 10 | Next 10 |
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, will present data highlighting the clinical utility of Guardant Health’s proprietary blood tests to make a meaningful impact on patient care at the upcoming virtual 2021 Ame...
The following slide deck was published by Guardant Health, Inc. in conjunction with this event. For further details see: Guardant Health (GH) Presents At J.P. Morgan Healthcare Conference - Slideshow
Guardant Health ([[GH]] +1.1%) will launch the first liquid biopsy test for detection of early-stage colon cancer recurrence in February, CEO Helmy Eltoukhy said. The test will be called Guardant Reveal.Reveal will have a seven-day turnaround time, Eltoukhy said in an interview. Addition...
Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average. A large short interest position and a nu...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. Guardant Health’s management is scheduled to present on Monday, January 11 at 7:5...
Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...
Guardant Health (GH) names Michael Bell as the new CFO effective January 5, 2021. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its successful transition as a public company.Helmy Eltoukhy, CEO said, “M...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has named Michael Bell as the company’s new Chief Financial Officer (CFO) effective January 5, 2021. Michael will succeed Derek Bertocci who has retired after successfully ushering the company through its s...
Platform Uncovers Key Clinical-Genomic Insights in Patients Treated with Endocrine Therapy and CDK4/6 Inhibitors for Use in Precision Oncology Drug Development Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, shares new data at the 2020 Virtual San A...
The oncology market covers every area of cancer care, from diagnosis to treatment, and is one of the biggest sectors in the life science space. Cancer is the second leading cause of death worldwide, after cardiovascular diseases. Biotechnology and pharmaceutical companie...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...